Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
Ionizing radiation emitter
DRUG CLASS:
Ionizing radiation emitter
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
177Lu-satetraxetan-lilotomab (4)
lutetium Lu 177 vipivotide tetraxetan (4)
ibritumomab tiuxetan (3)
AAA614 (2)
Actinium-225 conjugated to daratumumab (2)
lutetium Lu 177 dotatate (2)
PNT2002 (2)
radium Ra-223 dichloride (2)
CLR 131 (2)
TLX250 (0)
177Lu-DTPA-omburtamab (0)
177Lu-LNC1003 (0)
177Lu-LNC1004 (0)
177Lu-LNC1010 (0)
177Lu-P17-087 (0)
177Lu-P17-088 (0)
177Lu-PSMA-R2 (0)
CYT 500 (0)
TLX591 (0)
90Y-NM600 (0)
TLX66 (0)
AAA603 (0)
iodine I 131 tositumomab (0)
CAM-H2 (0)
samarium-153 DOTMP (0)
Debio 0228 (0)
EBTATE (0)
FF21101 (0)
ITM-31 (0)
epratuzumab Y-90 (0)
MVT-1075 (0)
186Re (0)
Radspherin (0)
lutetium-177 DOTA satoreotide (0)
67Cu MeCOSar octreotate (0)
177Lu-edotreotide (0)
Re (0)
PNT2003 (0)
177Lu-satetraxetan-lilotomab (4)
lutetium Lu 177 vipivotide tetraxetan (4)
ibritumomab tiuxetan (3)
AAA614 (2)
Actinium-225 conjugated to daratumumab (2)
lutetium Lu 177 dotatate (2)
PNT2002 (2)
radium Ra-223 dichloride (2)
CLR 131 (2)
TLX250 (0)
177Lu-DTPA-omburtamab (0)
177Lu-LNC1003 (0)
177Lu-LNC1004 (0)
177Lu-LNC1010 (0)
177Lu-P17-087 (0)
177Lu-P17-088 (0)
177Lu-PSMA-R2 (0)
CYT 500 (0)
TLX591 (0)
90Y-NM600 (0)
TLX66 (0)
AAA603 (0)
iodine I 131 tositumomab (0)
CAM-H2 (0)
samarium-153 DOTMP (0)
Debio 0228 (0)
EBTATE (0)
FF21101 (0)
ITM-31 (0)
epratuzumab Y-90 (0)
MVT-1075 (0)
186Re (0)
Radspherin (0)
lutetium-177 DOTA satoreotide (0)
67Cu MeCOSar octreotate (0)
177Lu-edotreotide (0)
Re (0)
PNT2003 (0)
›
Associations
(23)
News
Trials
VERI cancer hierarchy
Reset Filters
CD20 positive
Follicular Lymphoma
CD20 positive
Follicular Lymphoma
rituximab + ibritumomab tiuxetan
Sensitive: A1 - Approval
rituximab + ibritumomab tiuxetan
Sensitive
:
A1
rituximab + ibritumomab tiuxetan
Sensitive: A1 - Approval
rituximab + ibritumomab tiuxetan
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
ibritumomab tiuxetan
Sensitive: A1 - Approval
ibritumomab tiuxetan
Sensitive
:
A1
ibritumomab tiuxetan
Sensitive: A1 - Approval
ibritumomab tiuxetan
Sensitive
:
A1
FOLH1 positive
Prostate Cancer
FOLH1 positive
Prostate Cancer
lutetium Lu 177 vipivotide tetraxetan
Sensitive: A1 - Approval
lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
A1
lutetium Lu 177 vipivotide tetraxetan
Sensitive: A1 - Approval
lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
A1
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
ibritumomab tiuxetan
Sensitive: A2 - Guideline
ibritumomab tiuxetan
Sensitive
:
A2
ibritumomab tiuxetan
Sensitive: A2 - Guideline
ibritumomab tiuxetan
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
CLR 131
Sensitive: B - Late Trials
CLR 131
Sensitive
:
B
CLR 131
Sensitive: B - Late Trials
CLR 131
Sensitive
:
B
No biomarker
Lymphoplasmacytic Lymphoma
No biomarker
Lymphoplasmacytic Lymphoma
CLR 131
Sensitive: B - Late Trials
CLR 131
Sensitive
:
B
CLR 131
Sensitive: B - Late Trials
CLR 131
Sensitive
:
B
SSTR positive
Neuroendocrine Tumor
SSTR positive
Neuroendocrine Tumor
lutetium Lu 177 dotatate
Sensitive: B - Late Trials
lutetium Lu 177 dotatate
Sensitive
:
B
lutetium Lu 177 dotatate
Sensitive: B - Late Trials
lutetium Lu 177 dotatate
Sensitive
:
B
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
lutetium Lu 177 vipivotide tetraxetan
Sensitive: B - Late Trials
lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
B
lutetium Lu 177 vipivotide tetraxetan
Sensitive: B - Late Trials
lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
B
FOLH1 expression
Prostate Cancer
FOLH1 expression
Prostate Cancer
PNT2002
Sensitive: B - Late Trials
PNT2002
Sensitive
:
B
PNT2002
Sensitive: B - Late Trials
PNT2002
Sensitive
:
B
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
PNT2002
Sensitive: B - Late Trials
PNT2002
Sensitive
:
B
PNT2002
Sensitive: B - Late Trials
PNT2002
Sensitive
:
B
FOLH1 expression
Prostate Cancer
FOLH1 expression
Prostate Cancer
pembrolizumab + lutetium Lu 177 vipivotide tetraxetan
Sensitive: C3 – Early Trials
pembrolizumab + lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
C3
pembrolizumab + lutetium Lu 177 vipivotide tetraxetan
Sensitive: C3 – Early Trials
pembrolizumab + lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
C3
TMPRSS2-ERG fusion
Prostate Cancer
TMPRSS2-ERG fusion
Prostate Cancer
radium Ra-223 dichloride
Resistant: C3 – Early Trials
radium Ra-223 dichloride
Resistant
:
C3
radium Ra-223 dichloride
Resistant: C3 – Early Trials
radium Ra-223 dichloride
Resistant
:
C3
RB deletion
Prostate Cancer
RB deletion
Prostate Cancer
radium Ra-223 dichloride
Resistant: C3 – Early Trials
radium Ra-223 dichloride
Resistant
:
C3
radium Ra-223 dichloride
Resistant: C3 – Early Trials
radium Ra-223 dichloride
Resistant
:
C3
ATM mutation
Prostate Cancer
ATM mutation
Prostate Cancer
enzalutamide capsule + lutetium Lu 177 vipivotide tetraxetan
Sensitive: C4 – Case Studies
enzalutamide capsule + lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
C4
enzalutamide capsule + lutetium Lu 177 vipivotide tetraxetan
Sensitive: C4 – Case Studies
enzalutamide capsule + lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
C4
FAP expression
Sarcoma
FAP expression
Sarcoma
AAA614
Sensitive: D – Preclinical
AAA614
Sensitive
:
D
AAA614
Sensitive: D – Preclinical
AAA614
Sensitive
:
D
FAP expression
Pancreatic Cancer
FAP expression
Pancreatic Cancer
AAA614
Sensitive: D – Preclinical
AAA614
Sensitive
:
D
AAA614
Sensitive: D – Preclinical
AAA614
Sensitive
:
D
ERBB3 expression
Renal Cell Carcinoma
ERBB3 expression
Renal Cell Carcinoma
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
177Lu-satetraxetan-lilotomab
Sensitive
:
D
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
177Lu-satetraxetan-lilotomab
Sensitive
:
D
ERBB3 expression
Prostate Cancer
ERBB3 expression
Prostate Cancer
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
177Lu-satetraxetan-lilotomab
Sensitive
:
D
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
177Lu-satetraxetan-lilotomab
Sensitive
:
D
ERBB3 expression
Colorectal Cancer
ERBB3 expression
Colorectal Cancer
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
177Lu-satetraxetan-lilotomab
Sensitive
:
D
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
177Lu-satetraxetan-lilotomab
Sensitive
:
D
ERBB3 expression
Ovarian Cancer
ERBB3 expression
Ovarian Cancer
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
177Lu-satetraxetan-lilotomab
Sensitive
:
D
177Lu-satetraxetan-lilotomab
Sensitive: D – Preclinical
177Lu-satetraxetan-lilotomab
Sensitive
:
D
SSTR2 underexpression
Neuroendocrine Tumor
SSTR2 underexpression
Neuroendocrine Tumor
lutetium Lu 177 dotatate
Sensitive: D – Preclinical
lutetium Lu 177 dotatate
Sensitive
:
D
lutetium Lu 177 dotatate
Sensitive: D – Preclinical
lutetium Lu 177 dotatate
Sensitive
:
D
CD38 positive
Multiple Myeloma
CD38 positive
Multiple Myeloma
Actinium-225 conjugated to daratumumab
Sensitive: D – Preclinical
Actinium-225 conjugated to daratumumab
Sensitive
:
D
Actinium-225 conjugated to daratumumab
Sensitive: D – Preclinical
Actinium-225 conjugated to daratumumab
Sensitive
:
D
CD38 positive
Burkitt Lymphoma
CD38 positive
Burkitt Lymphoma
Actinium-225 conjugated to daratumumab
Sensitive: D – Preclinical
Actinium-225 conjugated to daratumumab
Sensitive
:
D
Actinium-225 conjugated to daratumumab
Sensitive: D – Preclinical
Actinium-225 conjugated to daratumumab
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login